Yoshio Okano

Randomized Phase III Trial of Erlotinib Versus Docetaxel As Second- or Third-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA)

Tomoya Kawaguchi, Masahiko Ando, Kazuhiro Asami et al. · Journal of Clinical Oncology · 2014 · 263 citations · Full text

Medicine, Oncology, Pharmacology +16

Synthesis and Secretion of Interleukin-15 by Freshly Isolated Human Bronchial Epithelial Cells

Ning Ge, Yasuhiko Nishioka, Yoichi Nakamura et al. · International Archives of Allergy and Immunology · 2004 · 40 citations

Life Sciences, Immunology, Oncology +13

Randomized phase III trial of erlotinib (E) versus docetaxel (D) as second- or third-line therapy in patients with advanced non-small cell lung cancer (NSCLC) who have wild-type or mutant epidermal growth factor receptor (EGFR): Docetaxel and Erlotinib Lung Cancer Trial (DELTA).

Yoshio Okano, Masahiko Ando, Kazuhiro Asami et al. · Journal of Clinical Oncology · 2013 · 39 citations

Medicine, Oncology, Pharmacology +15

Early-phase Neutrophilia in Cigarette Smoke-induced Acute Eosinophilic Pneumonia

Keisuke MlKI, Mari MlKl, Yoichi Nakamura et al. · Internal Medicine · 2003 · 30 citations

Veterinary Medicine, Immunology, Pathobiology +17

Pretreatment eosinophil counts as a predictive biomarker in non‐small cell lung cancer patients treated with immune checkpoint inhibitors

Eiji Takeuchi, Kensuke Kondo, Yoshio Okano et al. · Thoracic Cancer · 2023 · 25 citations · Full text

Life Sciences, Immunology, Oncology +17